The 21-year-old woman was in agony. For five years, her own body had waged a violent war against her colon. She had ...

Engineered T cells that have been used to treat ulcerative colitis, rheumatoid arthritis and lupus show promising results.

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...

Cellular therapies, including TIL, TCR, and CAR-T, are transforming lung cancer care by utilizing personalized immune cells to target tumors. TIL therapy, now FDA-approved for solid tumors, shows ...

With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer.

Sequential ICV and IV administration of CR7-GD2 CAR T-cell therapy showed improved tolerability over concurrent dosing in ...

The CAR T Vision Steering Committee has set an ambitious goal: to double the proportion of eligible patients treated with CAR T by 2030. 2 Reimbursement challenges stand out as an area where ...

A new study published in the journal Nature reports results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3 (GPC3). Researchers ...

A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer ...

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer. Investigators from Baylor College of Medicine, ...